Tokyo, Dec. 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060118) titled 'A database study on the expression of immune-related adverse events in immune checkpoint inhibitors in combination with chemotherapy for non-squamous cell carcinoma' on Dec. 18.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Non-squamous cell carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Confirmation of safety in patients who received immune checkpoint inhibitors in combination with chemotherapy in non-squamous cell carcinoma
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Non-squamous cell carcinoma and administration of targeted drugs
Key exclusion criteria - Patients with no covariates and no previous administration of the target drug
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 12 Month 16 Day
Anticipated trial start date - 2025 Year 12 Month 16 Day
Last follow-up date - 2025 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068757
Disclaimer: Curated by HT Syndication.
